PI Industries Q2 FY26 results: revenue down about 18 percent year on year

Revenue DeclineResults View source PDF Explain this filing

PIIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.1%Reaction day

₹3772.10

prior close

₹3750.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.8%-5.9% vs market

Pesticides & Agrochemicals peers, median of 26sector+0.3%-5.4% vs sector

On the reaction day the stock moved 5.9 pts less than Nifty Midcap 150 and 5.4 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-0.6

15m

-0.9

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.1+0.8-5.9+0.3-5.4

Next day

-5.2+0.4-5.6+0.5-5.7

-5.5+0.5-6.0-1.5-4.0

-6.0+1.2-7.2-0.4-5.6

-8.3+0.5-8.8-0.7-7.5

-9.0+0.9-9.9-1.3-7.7

-8.9-0.3-8.6-0.7-8.3

15d

-10.7-0.4-10.3-1.2-9.6

-12.1-0.3-11.8-3.9-8.2

-13.7-1.2-12.4-7.6-6.1

-16.1+0.1-16.3-9.5-6.6

UpDownMarket · Nifty Midcap 150Sector · Pesticides & Agrochemicals peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

PI Industries posted a weak Q2 FY26. Standalone revenue fell about 18 percent to Rs 17,526 Mn from Rs 21,312 Mn a year ago, with PAT down about 12 percent to Rs 4,911 Mn. Consolidated revenue declined about 16 percent to Rs 18,723 Mn and PAT fell about 19 percent to Rs 4,093 Mn. The Agrochemicals segment remained the main earner while the Pharma segment continued to report losses of Rs 819 Mn in the quarter. Limited review by Price Waterhouse was clean with no qualifications.

Likely market impact

Soft quarter with revenue and profit declines and persistent Pharma losses may weigh on the stock near term.